• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

粒径差异化的纳米脂质载体的制备和表征

李会鹏, 苏志桂, 陈明磊, 孟凡飞, 孙敏捷, 王岩, 张灿, 平其能

李会鹏, 苏志桂, 陈明磊, 孟凡飞, 孙敏捷, 王岩, 张灿, 平其能. 粒径差异化的纳米脂质载体的制备和表征[J]. 中国药科大学学报, 2015, 46(4): 436-443. DOI: 10.11665/j.issn.1000-5048.20150409
引用本文: 李会鹏, 苏志桂, 陈明磊, 孟凡飞, 孙敏捷, 王岩, 张灿, 平其能. 粒径差异化的纳米脂质载体的制备和表征[J]. 中国药科大学学报, 2015, 46(4): 436-443. DOI: 10.11665/j.issn.1000-5048.20150409
shu
LI Huipeng, SU Zhigui, CHEN Minglei, MENG Fanfei, SUN Minjie, WANG Yan, ZHANG Can, PING Qineng. Preparation and characterization of nanostructured lipid carriers with difference in particle size[J]. Journal of China Pharmaceutical University, 2015, 46(4): 436-443. DOI: 10.11665/j.issn.1000-5048.20150409
Citation: LI Huipeng, SU Zhigui, CHEN Minglei, MENG Fanfei, SUN Minjie, WANG Yan, ZHANG Can, PING Qineng. Preparation and characterization of nanostructured lipid carriers with difference in particle size[J]. Journal of China Pharmaceutical University, 2015, 46(4): 436-443. DOI: 10.11665/j.issn.1000-5048.20150409
shu

粒径差异化的纳米脂质载体的制备和表征

  • 1.

    中国药科大学药剂学教研室

  • 2.

    新药研究中心

基金项目: 国家自然科学基金资助项目(No.81273467)

Preparation and characterization of nanostructured lipid carriers with difference in particle size

摘要

    摘要
  • 摘要: 利用特色化的中心复合设计，以香豆素-6为模型药物，通过控制特定的因素和指标，制备粒径不同而其他性质相同的纳米脂质载体(NLCs)，并对其形态、Zeta电位和包封率等理化性质进行研究。通过体外稳定性实验考察NLCs在K-R液和PBS缓冲液中的稳定性，同时以透析法研究制剂的体外释药行为特性。采用MTT法研究空白NLCs和载药NLCs的细胞毒性，活体成像技术考察NLCs在小鼠胃肠道中的滞留时间。结果显示:制备所得的粒径分别为100，200及300 nm的香豆素-6纳米脂质载体，分散性良好，在K-R液和PBS缓冲液中可以稳定存在，并且体外24 h香豆素-6的累积释放量均不超过总量的7%。MTT实验表明:空白NLCs和载药NLCs对Caco-2毒性较小。小鼠肠内滞留试验显示:NLCs在灌胃给药6 h后仍然能够在胃肠道中检测到。因此，制备得到的不同粒径NLCs可以作为模型制剂，用于细胞水平和动物水平上研究NLCs粒径对口服吸收的影响。
    Abstract: To construct nanostructured lipid carriers(NLCs)with different particle sizes but the same other physicochemical properties, central composite design was adopted. Coumarin-6(C-6)was selected as the model drug due to its high lipophilicity and high fluorescence intensity. Physicochemical properties of NLCs with 100 nm, 200 nm and 300 nm in particle size could remain stable during certain time in K-R solution and PBS. Release experiments in vitro showed that cumulative release of C-6 in NLCs was less than 7% after 24 h. The MTT assay indicated that both blank NLCs and C-6 loaded NLCs showed low toxicity. To confirm the integrity of NLCs in gastrointestinal tract, DiR-loaded NLCs were prepared and the distribution in vivo was monitored by fluorescence imaging. After 6 h oral administration, intact DiR-loaded NLCs could stiu be found, suggesting that NLCs could be used to characterize the uptake in gastrointestinal tract.
    • HTML全文
    • 参考文献(15)
  • [1] Patel VF,Liu F,Brown MB.Advances in oral transmucosal drug delivery[J].J Control Release,2011,153(2):106-116.
    [2] Ensign LM,Cone R,Hanes J.Oral drug delivery with polymeric nanoparticles:the gastrointestinal mucus barriers[J].Adv Drug Deliver Rev,2012,64(6):557-570.
    [3] Schenk M,Mueller C.The mucosal immune system at the gastrointestinal barrier[J].Best Pract Res Clin Gastroenterol,2008,22(6):391-409.
    [4] Yuan H,Wang LL,Du YZ,et al.Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification[J].Colloid Surface B,2007,60(2):174-179.
    [5] Jung T,Kamm W,Breitenbach A,et al.Biodegradable nanoparticles for oral delivery of peptides:is there a role for polymers to affect mucosal uptake[J]? Eur J Pharm Biopharm,2000,50(1):147-160.
    [6] Des Rieux A,Ragnarsson EGE,GullbergE,et al.Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium[J].Eur J Pharm Sci,2005,25(4/5):455-465.
    [7] Joshi M,Patravale V.Nanostructured lipid carrier(NLC)based gel of celecoxib[J].Int J Pharm,2008,346(1/2):124-132.
    [8] Albanese A,Tang PS,Chan WCW.The effect of nanoparticle size,shape,and surface chemistry on biological systems[J].Annu Rev Biomed Eng,2012,14:1-16.
    [9] Muller RH,Petersen RD,HornmossA,et al.Nanostructured lipid carriers(NLC)in cosmetic dermal products[J].Adv Drug Deliver Rev,2007,59(6):522-530.
    [10] Chen HB,Zheng Y,Tian G,et al.Oraldelivery of DMAB-modified docetaxel-loaded PLGA-TPGS nanoparticles for cancer chemotherapy[J].Nanoscale Res Lett,2011,6(1):4.
    [11] Muller RH,Radtke M,Wissing SA.Nanostructured lipid matrices for improved microencapsulation of drugs[J].Int J Pharm,2002,242(1/2):121-128.
    [12] Souto EB,Mehnert W,Muller RH.Polymorphic behavior of Compritol(R)888 ATO as bulk lipid and as SLN and NLC[J] J Microencapsul,2006,23(4):417-433.
    [13] Pardeike J,Hommoss A,Muller RH.Lipid nanoparticles(SLN,NLC)in cosmetic and pharmaceutical dermal products[J].Int J Pharm,2009,366(1/2):170-84.
    [14] Shi YP,Su ZG,Li S,et al.Multisteptargeted nanodrug delivery system aiming at leukemic stem cells and minimal residual disease[J].Mol Pharm,2013,10(6):2479-2489.
    [15] Su ZG,Shi YP,Xiao YY,et al.Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrierin vivo after optimization[J].Int J Pharm,2013,447(1/2):281-292.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1255
  • HTML全文浏览量:  2
  • PDF下载量:  1465
  • 被引次数: 0
出版历程
  • 刊出日期:  2015-08-24

目录

摘要
HTML全文
    参考文献(15)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：315696

    x 关闭 永久关闭